Barclays Cuts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $9.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price decreased by equities researchers at Barclays from $11.00 to $9.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential upside of 31.20% from the company’s previous close.

A number of other research analysts also recently commented on BCRX. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. TD Cowen began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target for the company. Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald increased their target price on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $18.82.

BioCryst Pharmaceuticals Stock Down 6.3%

Shares of BCRX stock opened at $6.86 on Tuesday. The stock has a market cap of $1.44 billion, a P/E ratio of -38.11 and a beta of 1.05. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31. The company’s fifty day simple moving average is $7.56 and its two-hundred day simple moving average is $8.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $159.40 million for the quarter, compared to analysts’ expectations of $162.91 million. During the same period last year, the firm posted ($0.07) earnings per share. The company’s revenue was up 36.1% compared to the same quarter last year. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director directly owned 65,352 shares in the company, valued at $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals by 29.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 434,531 shares of the biotechnology company’s stock worth $3,298,000 after acquiring an additional 98,436 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in BioCryst Pharmaceuticals by 128.8% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 41,169 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 23,177 shares in the last quarter. QTR Family Wealth LLC grew its holdings in BioCryst Pharmaceuticals by 3.4% during the 3rd quarter. QTR Family Wealth LLC now owns 157,137 shares of the biotechnology company’s stock worth $1,193,000 after acquiring an additional 5,151 shares in the last quarter. Csenge Advisory Group bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth about $190,000. Finally, State of Alaska Department of Revenue bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth about $90,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.